Edoxaban Steady-State PK/PD in Adults With Nephrotic Syndrome

NANot yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 30, 2025

Primary Completion Date

February 28, 2026

Study Completion Date

February 28, 2026

Conditions

Nephrotic SyndromeHypoalbuminemia

Interventions

DRUG

Edoxaban 60 mg

film-coated tablet, manufactured by Daiichi Sankyo Europe GmbH

DRUG

Enoxaparin 40 mg

enoxaparin sodium, prefilled syringe of 0.4mL injectable solution, manufactured by SANOFI WINTHROP INDUSTRIE

All Listed Sponsors

collaborator

Chinese Academy of Medical Sciences, Fuwai Hospital

OTHER

lead

Peking University People's Hospital

OTHER

NCT07116239 - Edoxaban Steady-State PK/PD in Adults With Nephrotic Syndrome | Biotech Hunter | Biotech Hunter